You are here: Industry Insights > Market News > Gufic Biosciences gets Tigecycline patent by Eurasian Patent Office

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

HydroLinX® Water for Injection in Bags

Crude Semaglutide

Clopidogrel Sulfate

Carbocisteine

HydroLinX® Buffer Solutions and Process Liquids

Canagliflozin

Gufic Biosciences gets Tigecycline patent by Eurasian Patent Office

expresspharmaNovember 30, 2020

Tag: Gufic Biosciences , tigecycline , pneumonia

Favorites

Gufic Biosciences have been granted patent by the Eurasian Patent office (EAPO) for its invention of “A Freeze Dried Parenteral Composition of Tigecycline and Process for Preparation Thereof.”

Tigecycline is a tetracycline antibiotic medication used for a number of bacterial infections and is used to treat certain serious infections including community acquired pneumonia (a lung infection that developed in a person who was not in the hospital), skin infections, and infections of the abdomen.

Further, EAPO member States are Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russian Federation, Tajikistan and Turkmenistan.

Previous:Dr Reddy’s to acquire select anti-allergy brands from Glenmark in Russia and other CIS countries

Next:Modi visits key vaccine facilities as COVID-19 case load surges

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Gufic Biosciences gets Tigecycline patent by Eurasian Patent Office | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Gufic Biosciences gets Tigecycline patent by Eurasian Patent Office

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Gufic Biosciences gets Tigecycline patent by Eurasian Patent Office

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>